Concord Biotech Limited — Board Meeting, 29-05-2025: Outcome of Board Meeting

Concord Biotech has announced a board meeting on which it approved the audited consolidated financial results for the quarter and financial year ended March 31, 2025. Revenue rose to Rs. 1244.5 Cr from Rs. 1050.7 Cr, while profit after tax jumped to Rs. 371.6 Cr from Rs. 308.1 Cr. The board proposed a dividend of Rs. 10.70 per share. Key updates include appointing Ms. Hina Patel as Company Secretary and Compliance Officer, along with new auditors for secretarial, internal, and cost audits for FY26. The company is ramping up capacity with strong operational cash flows.